Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR TO COMMENCE SECOND CLINICAL TRIAL WITH AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR TYPE 2 DIABETES
Clinical Trial Application approved
EU Phase I clinical trial expected to commence in December 2022
Cambridge, UK, 22 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces the BASG (Bundesamt für Sicherheit im Gesundheitswesen) clearance of the Group’s Clinical Trial Application (CTA) for AT278, an ultra-rapid acting,…
The granted patents further strengthen the Group’s extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio
Cambridge, UK, 22 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the Japan Patent Office has granted a patent (JP7145849) protecting novel formulations of the Group’s proprietary insulin products, AT247 and AT278. The same patent has also been granted in South Korea.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented…
Newly built Research & Development (R&D) space is available at the Peterborough Research & Innovation Centre on Bishops Road, PE1 5BW.
The Research & Innovation Centre is set to provide a hub for science and technology businesses in Peterborough. Due for completion by the end of 2022, the building will be located adjacent to the newly opened ARU Peterborough campus. The building will seek to strengthen links between academia and industry, establish skills and learning in the very heart of the city, and provide a platform for an innovation eco-system with a university at…
In May 2022, we were honored to announce our collaboration with the Future of Work Institute (FOWI) to enhance our Employer of Choice webinar series to provide our members with real world insights, guidance, and best practices on becoming employers of choice to attract and develop their best team.
Fast forward five months and we have learnt how to; become a destination workplace, support our employees and colleagues through wellbeing strategies, overcome the challenges around hybrid working and finally, to become a great storyteller.
It has been a pleasure to work with expert facilitators,…
Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has made a number of strategic internal promotions to strengthen its Executive and Management teams. This expansion marks a period of ongoing growth for Domainex, and the newly bolstered teams will be pivotal in driving further development of the company.
Dr Natalie Winfield and Dr Catherine Stace immediately join the Executive Team, with Natalie taking on the position of Executive Director of Commercial Operations and Catherine the position of Executive Director of Business Development…
Cambridge, UK, 21st November 2022: Babraham Research Campus Ltd, which is responsible for the development and management of the Babraham Research Campus is delighted to announce the appointment of Dr Kathryn Chapman to the newly created role of Director, Science & Entrepreneurship.
Kathryn is a highly experienced bioscience professional with 10 years research experience in academia and industry and over 15 years’ experience in strategic roles at the NC3Rs, UKRI and the University of Cambridge.
Further to a research career concentrated on disease modelling and target…
Cambridge, UK, 10 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.
Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a differentiated, stable, liquid drug product, for…
Leading global drug development consultancy Boyds has appointed experienced regulatory affairs professional and cell and gene therapy expert Dr Patrick Ginty.
With 17 years’ R&D and regulatory affairs experience in regenerative medicine and cell and gene therapy products, Patrick joins Boyds as Senior Director of Regulatory Affairs.
Most recently, Patrick was Head of Regulatory Affairs at AviadoBio, a biotechnology company developing gene therapies for neurodegenerative diseases. Prior to this, he was Head of Gene Therapy Regulatory Affairs at Handl Therapeutics (a fully owned subsidiary…
Cambridge, UK, 15th November 2022 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has made a number of strategic internal promotions to strengthen its Executive and Management teams. This expansion marks a period of ongoing growth for Domainex, and the newly bolstered teams will be pivotal in driving further development of the company.
Dr Natalie Winfield and Dr Catherine Stace immediately join the Executive Team, with Natalie taking on the position of Executive Director of Commercial Operations and Catherine the…